Index - 2021

2021 / 2020 / 2019 / 2018



  • Overig
  • Thema-artikelH
  • Let op!LO
  • Nieuw
A
acenocoumarol DOAC 202183-88 PCC 202183-88 andexanet alfa 202183-88 antidota 202183-88 apixaban 202183-88 bloedingen 202183-88 bloedstolling 202183-88 bloedverdunners 202183-88 cumarinederivaten 202183-88 dabigatran 202183-88 directe trombineremmers 202183-88 factor Xa-remmers 202183-88 fenprocoumon 202183-88 idarucizumab 202183-88 protrombinecomplexconcentraat 202183-88 rivaroxaban 202183-88 vitamine K-antagonisten 202183-88 Ad26.COV2-S-vaccin AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 afvallen GLP-1-agonist 202189-94 bloedglucoseverlagende geneesmiddelen 202189-94 diabetes mellitus type 2 202189-94 gewichtsverlies 202189-94 liraglutide 202189-94 obesitas 202189-94 overgewicht 202189-94 semaglutide 202189-94 AIS CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 Aktiprol® amisulpride 202121-28 antipsychotica 202121-28 bijwerkingen 202121-28 meta-analyse 202121-28 netwerk meta-analyse 202121-28 amiodaron T3 202195-99 T4 202195-99 TRH 202195-99 TSH 202195-99 asparaginase 202195-99 biotine 202195-99 carbamazepine 202195-99 danazol 202195-99 fenytoïne 202195-99 fluorouracil 202195-99 furosemide 202195-99 laboratoriumbepalingen 202195-99 levothyroxine 202195-99 liothyronine 202195-99 methadon 202195-99 niacine 202195-99 perfenazine 202195-99 schildklier 202195-99 schildklierfunctiestoornis 202195-99 schildklierhormonen 202195-99 schildklierwaarden 202195-99 thyroxine 202195-99 vitamine B3 202195-99 vitamine B8 202195-99 voedingssupplementen 202195-99 amisulpride Aktiprol® 202121-28 antipsychotica 202121-28 bijwerkingen 202121-28 meta-analyse 202121-28 netwerk meta-analyse 202121-28 amputatie canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 andexanet alfa DOAC 202183-88 PCC 202183-88 acenocoumarol 202183-88 antidota 202183-88 apixaban 202183-88 bloedingen 202183-88 bloedstolling 202183-88 bloedverdunners 202183-88 cumarinederivaten 202183-88 dabigatran 202183-88 directe trombineremmers 202183-88 factor Xa-remmers 202183-88 fenprocoumon 202183-88 idarucizumab 202183-88 protrombinecomplexconcentraat 202183-88 rivaroxaban 202183-88 vitamine K-antagonisten 202183-88 angina CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 antidota DOAC 202183-88 PCC 202183-88 acenocoumarol 202183-88 andexanet alfa 202183-88 apixaban 202183-88 bloedingen 202183-88 bloedstolling 202183-88 bloedverdunners 202183-88 cumarinederivaten 202183-88 dabigatran 202183-88 directe trombineremmers 202183-88 factor Xa-remmers 202183-88 fenprocoumon 202183-88 idarucizumab 202183-88 protrombinecomplexconcentraat 202183-88 rivaroxaban 202183-88 vitamine K-antagonisten 202183-88 antipsychotica Aktiprol® 202121-28 amisulpride 202121-28 bijwerkingen 202121-28 meta-analyse 202121-28 netwerk meta-analyse 202121-28 apixaban DOAC 202183-88 PCC 202183-88 acenocoumarol 202183-88 andexanet alfa 202183-88 antidota 202183-88 bloedingen 202183-88 bloedstolling 202183-88 bloedverdunners 202183-88 cumarinederivaten 202183-88 dabigatran 202183-88 directe trombineremmers 202183-88 factor Xa-remmers 202183-88 fenprocoumon 202183-88 idarucizumab 202183-88 protrombinecomplexconcentraat 202183-88 rivaroxaban 202183-88 vitamine K-antagonisten 202183-88 aritmie atrium flutter 202117-20 atriumfibrilleren 202117-20 hartritmestoornis 202117-20 medisch hulpmiddel 202117-20 medische app 202117-20 screening 202117-20 asparaginase T3 202195-99 T4 202195-99 TRH 202195-99 TSH 202195-99 amiodaron 202195-99 biotine 202195-99 carbamazepine 202195-99 danazol 202195-99 fenytoïne 202195-99 fluorouracil 202195-99 furosemide 202195-99 laboratoriumbepalingen 202195-99 levothyroxine 202195-99 liothyronine 202195-99 methadon 202195-99 niacine 202195-99 perfenazine 202195-99 schildklier 202195-99 schildklierfunctiestoornis 202195-99 schildklierhormonen 202195-99 schildklierwaarden 202195-99 thyroxine 202195-99 vitamine B3 202195-99 vitamine B8 202195-99 voedingssupplementen 202195-99 AstraZenica Ad26.COV2-S-vaccin 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 atrium flutter aritmie 202117-20 atriumfibrilleren 202117-20 hartritmestoornis 202117-20 medisch hulpmiddel 202117-20 medische app 202117-20 screening 202117-20 atriumfibrilleren aritmie 202117-20 atrium flutter 202117-20 hartritmestoornis 202117-20 medisch hulpmiddel 202117-20 medische app 202117-20 screening 202117-20
B
baarmoederhalskanker AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 bamlanivimab SARS-CoV-2 202169-73 casirivimab 202169-73 covid-19 202169-73 covidpandemie 202169-73 covidpatiënten 202169-73 etesevimab 202169-73 imdevimab 202169-73 immuungecompromitteerden 202169-73 longcovid 202169-73 monoklonale antilichamen 202169-73 neutraliserende monoklonale antilichamen 202169-73 pandemie 202169-73 regdanvimab 202169-73 sotrovimab 202169-73 beademing COVID-19 202178-82 ECMO 202178-82 IMV 202178-82 SARS-CoV-2 202178-82 corticosteroïden 202178-82 covidpneumonie 202178-82 dexamethason 202178-82 hydrocortison 202178-82 inhalatiecorticosteroïden 202178-82 methylprednisolon 202178-82 pandemie 202178-82 zuurstoftherapie 202178-82 beroerte CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 beschermingsduur COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 bijwerkingen Aktiprol® 202121-28 EMA 202157-62 FDA 202157-62 amisulpride 202121-28 antipsychotica 202121-28 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 epidemiologisch onderzoek 20215-7 gerandomiseerd onderzoek 202157-62 meta-analyse 202121-28 myocardinfarct 202157-62 netwerk meta-analyse 202121-28 observationeel onderzoek 202157-62 post-marketing surveillance 20215-7 registratie 202157-62 registratieonderzoek 20215-7 richtlijnen 202157-62 rosiglitazon 202157-62 vaccins 20215-7 vaccinvigilantie 20215-7 biotine T3 202195-99 T4 202195-99 TRH 202195-99 TSH 202195-99 amiodaron 202195-99 asparaginase 202195-99 carbamazepine 202195-99 danazol 202195-99 fenytoïne 202195-99 fluorouracil 202195-99 furosemide 202195-99 laboratoriumbepalingen 202195-99 levothyroxine 202195-99 liothyronine 202195-99 methadon 202195-99 niacine 202195-99 perfenazine 202195-99 schildklier 202195-99 schildklierfunctiestoornis 202195-99 schildklierhormonen 202195-99 schildklierwaarden 202195-99 thyroxine 202195-99 vitamine B3 202195-99 vitamine B8 202195-99 voedingssupplementen 202195-99 bivalent AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 bloedglucoseverlagende geneesmiddelen GLP-1-agonist 202189-94 afvallen 202189-94 diabetes mellitus type 2 202189-94 gewichtsverlies 202189-94 liraglutide 202189-94 obesitas 202189-94 overgewicht 202189-94 semaglutide 202189-94 bloedglucoseverlagende middel EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 bloedingen DOAC 202183-88 PCC 202183-88 acenocoumarol 202183-88 andexanet alfa 202183-88 antidota 202183-88 apixaban 202183-88 bloedstolling 202183-88 bloedverdunners 202183-88 cumarinederivaten 202183-88 dabigatran 202183-88 directe trombineremmers 202183-88 factor Xa-remmers 202183-88 fenprocoumon 202183-88 idarucizumab 202183-88 protrombinecomplexconcentraat 202183-88 rivaroxaban 202183-88 vitamine K-antagonisten 202183-88 bloedstolling DOAC 202183-88 PCC 202183-88 acenocoumarol 202183-88 andexanet alfa 202183-88 antidota 202183-88 apixaban 202183-88 bloedingen 202183-88 bloedverdunners 202183-88 cumarinederivaten 202183-88 dabigatran 202183-88 directe trombineremmers 202183-88 factor Xa-remmers 202183-88 fenprocoumon 202183-88 idarucizumab 202183-88 protrombinecomplexconcentraat 202183-88 rivaroxaban 202183-88 vitamine K-antagonisten 202183-88 bloedverdunners DOAC 202183-88 PCC 202183-88 acenocoumarol 202183-88 andexanet alfa 202183-88 antidota 202183-88 apixaban 202183-88 bloedingen 202183-88 bloedstolling 202183-88 cumarinederivaten 202183-88 dabigatran 202183-88 directe trombineremmers 202183-88 factor Xa-remmers 202183-88 fenprocoumon 202183-88 idarucizumab 202183-88 protrombinecomplexconcentraat 202183-88 rivaroxaban 202183-88 vitamine K-antagonisten 202183-88
C
canagliflozine amputatie 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 canakinumab MACE 202174-77 cardiovasculaire mortaliteit 202174-77 colchicine 202174-77 coronaire hartziekten 202174-77 in-stent-restenose 202174-77 myocardinfarct 202174-77 secundaire preventie 202174-77 stents 202174-77 CanSino Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 carbamazepine T3 202195-99 T4 202195-99 TRH 202195-99 TSH 202195-99 amiodaron 202195-99 asparaginase 202195-99 biotine 202195-99 danazol 202195-99 fenytoïne 202195-99 fluorouracil 202195-99 furosemide 202195-99 laboratoriumbepalingen 202195-99 levothyroxine 202195-99 liothyronine 202195-99 methadon 202195-99 niacine 202195-99 perfenazine 202195-99 schildklier 202195-99 schildklierfunctiestoornis 202195-99 schildklierhormonen 202195-99 schildklierwaarden 202195-99 thyroxine 202195-99 vitamine B3 202195-99 vitamine B8 202195-99 voedingssupplementen 202195-99 cardiovasculair CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 cardiovasculaire mortaliteit MACE 202174-77 canakinumab 202174-77 colchicine 202174-77 coronaire hartziekten 202174-77 in-stent-restenose 202174-77 myocardinfarct 202174-77 secundaire preventie 202174-77 stents 202174-77 casirivimab SARS-CoV-2 202169-73 bamlanivimab 202169-73 covid-19 202169-73 covidpandemie 202169-73 covidpatiënten 202169-73 etesevimab 202169-73 imdevimab 202169-73 immuungecompromitteerden 202169-73 longcovid 202169-73 monoklonale antilichamen 202169-73 neutraliserende monoklonale antilichamen 202169-73 pandemie 202169-73 regdanvimab 202169-73 sotrovimab 202169-73 cerebrovasculair CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 Cervarix AIS 202147-56 CRPS 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 cervixcarcinoom AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 ChAdOx1-S-vaccin Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 clopidogrel CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 colchicine MACE 202174-77 canakinumab 202174-77 cardiovasculaire mortaliteit 202174-77 coronaire hartziekten 202174-77 in-stent-restenose 202174-77 myocardinfarct 202174-77 secundaire preventie 202174-77 stents 202174-77 Comirnaty COVID-19 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 coronaire hartziekten MACE 202174-77 canakinumab 202174-77 cardiovasculaire mortaliteit 202174-77 colchicine 202174-77 in-stent-restenose 202174-77 myocardinfarct 202174-77 secundaire preventie 202174-77 stents 202174-77 corticosteroïden COVID-19 202163-68 COVID-19 202178-82 ECMO 202178-82 IMV 202178-82 SARS-CoV-2 202163-68 SARS-CoV-2 202178-82 beademing 202178-82 covidpneumonie 202163-68 covidpneumonie 202178-82 dexamethason 202163-68 dexamethason 202178-82 hydrocortison 202178-82 inhalatiecorticosteroïden 202178-82 interleukine-6-antagonist 202163-68 methylprednisolon 202178-82 pandemie 202163-68 pandemie 202178-82 sarilumab 202163-68 tocilizumab 202163-68 zuurstoftherapie 202163-68 zuurstoftherapie 202178-82 covid Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 COVID-19 Comirnaty 202113-16 ECMO 202178-82 IMV 202178-82 Moderna 202113-16 SARS-CoV-2 202113-16 SARS-CoV-2 202163-68 SARS-CoV-2 202178-82 beademing 202178-82 beschermingsduur 202113-16 corticosteroïden 202163-68 corticosteroïden 202178-82 covidpneumonie 202163-68 covidpneumonie 202178-82 dexamethason 202163-68 dexamethason 202178-82 doelgroep 202113-16 hydrocortison 202178-82 inhalatiecorticosteroïden 202178-82 interleukine-6-antagonist 202163-68 mRNA 202113-16 messenger-RNA 202113-16 methylprednisolon 202178-82 pandemie 202113-16 pandemie 202163-68 pandemie 202178-82 sarilumab 202163-68 tocilizumab 202163-68 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 zuurstoftherapie 202163-68 zuurstoftherapie 202178-82 covid-19 Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 SARS-CoV-2 202169-73 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 bamlanivimab 202169-73 casirivimab 202169-73 covid 202129-34 covidpandemie 202169-73 covidpatiënten 202169-73 etesevimab 202169-73 imdevimab 202169-73 immuungecompromitteerden 202169-73 longcovid 202169-73 monoklonale antilichamen 202169-73 neutraliserende monoklonale antilichamen 202169-73 pandemie 202129-34 pandemie 202169-73 regdanvimab 202169-73 sotrovimab 202169-73 vaccin 202129-34 covidpandemie SARS-CoV-2 202169-73 bamlanivimab 202169-73 casirivimab 202169-73 covid-19 202169-73 covidpatiënten 202169-73 etesevimab 202169-73 imdevimab 202169-73 immuungecompromitteerden 202169-73 longcovid 202169-73 monoklonale antilichamen 202169-73 neutraliserende monoklonale antilichamen 202169-73 pandemie 202169-73 regdanvimab 202169-73 sotrovimab 202169-73 covidpatiënten SARS-CoV-2 202169-73 bamlanivimab 202169-73 casirivimab 202169-73 covid-19 202169-73 covidpandemie 202169-73 etesevimab 202169-73 imdevimab 202169-73 immuungecompromitteerden 202169-73 longcovid 202169-73 monoklonale antilichamen 202169-73 neutraliserende monoklonale antilichamen 202169-73 pandemie 202169-73 regdanvimab 202169-73 sotrovimab 202169-73 covidpneumonie COVID-19 202163-68 COVID-19 202178-82 ECMO 202178-82 IMV 202178-82 SARS-CoV-2 202163-68 SARS-CoV-2 202178-82 beademing 202178-82 corticosteroïden 202163-68 corticosteroïden 202178-82 dexamethason 202163-68 dexamethason 202178-82 hydrocortison 202178-82 inhalatiecorticosteroïden 202178-82 interleukine-6-antagonist 202163-68 methylprednisolon 202178-82 pandemie 202163-68 pandemie 202178-82 sarilumab 202163-68 tocilizumab 202163-68 zuurstoftherapie 202163-68 zuurstoftherapie 202178-82 CRPS AIS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 cumarinederivaten DOAC 202183-88 PCC 202183-88 acenocoumarol 202183-88 andexanet alfa 202183-88 antidota 202183-88 apixaban 202183-88 bloedingen 202183-88 bloedstolling 202183-88 bloedverdunners 202183-88 dabigatran 202183-88 directe trombineremmers 202183-88 factor Xa-remmers 202183-88 fenprocoumon 202183-88 idarucizumab 202183-88 protrombinecomplexconcentraat 202183-88 rivaroxaban 202183-88 vitamine K-antagonisten 202183-88 CVA LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 CYP2C19 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 cytochroom P450 CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12
D
dabigatran DOAC 202183-88 PCC 202183-88 acenocoumarol 202183-88 andexanet alfa 202183-88 antidota 202183-88 apixaban 202183-88 bloedingen 202183-88 bloedstolling 202183-88 bloedverdunners 202183-88 cumarinederivaten 202183-88 directe trombineremmers 202183-88 factor Xa-remmers 202183-88 fenprocoumon 202183-88 idarucizumab 202183-88 protrombinecomplexconcentraat 202183-88 rivaroxaban 202183-88 vitamine K-antagonisten 202183-88 danazol T3 202195-99 T4 202195-99 TRH 202195-99 TSH 202195-99 amiodaron 202195-99 asparaginase 202195-99 biotine 202195-99 carbamazepine 202195-99 fenytoïne 202195-99 fluorouracil 202195-99 furosemide 202195-99 laboratoriumbepalingen 202195-99 levothyroxine 202195-99 liothyronine 202195-99 methadon 202195-99 niacine 202195-99 perfenazine 202195-99 schildklier 202195-99 schildklierfunctiestoornis 202195-99 schildklierhormonen 202195-99 schildklierwaarden 202195-99 thyroxine 202195-99 vitamine B3 202195-99 vitamine B8 202195-99 voedingssupplementen 202195-99 dapagliflozine amputatie 202141-46 canagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 dexamethason COVID-19 202163-68 COVID-19 202178-82 ECMO 202178-82 IMV 202178-82 SARS-CoV-2 202163-68 SARS-CoV-2 202178-82 beademing 202178-82 corticosteroïden 202163-68 corticosteroïden 202178-82 covidpneumonie 202163-68 covidpneumonie 202178-82 hydrocortison 202178-82 inhalatiecorticosteroïden 202178-82 interleukine-6-antagonist 202163-68 methylprednisolon 202178-82 pandemie 202163-68 pandemie 202178-82 sarilumab 202163-68 tocilizumab 202163-68 zuurstoftherapie 202163-68 zuurstoftherapie 202178-82 diabetes EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 diabetes mellitus type 2 GLP-1-agonist 202189-94 afvallen 202189-94 amputatie 202141-46 bloedglucoseverlagende geneesmiddelen 202189-94 canagliflozine 202141-46 dapagliflozine 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 gewichtsverlies 202189-94 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 liraglutide 202189-94 metformine 202141-46 obesitas 202189-94 overgewicht 202189-94 secundaire preventie 202141-46 semaglutide 202189-94 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 directe trombineremmers DOAC 202183-88 PCC 202183-88 acenocoumarol 202183-88 andexanet alfa 202183-88 antidota 202183-88 apixaban 202183-88 bloedingen 202183-88 bloedstolling 202183-88 bloedverdunners 202183-88 cumarinederivaten 202183-88 dabigatran 202183-88 factor Xa-remmers 202183-88 fenprocoumon 202183-88 idarucizumab 202183-88 protrombinecomplexconcentraat 202183-88 rivaroxaban 202183-88 vitamine K-antagonisten 202183-88 DOAC PCC 202183-88 acenocoumarol 202183-88 andexanet alfa 202183-88 antidota 202183-88 apixaban 202183-88 bloedingen 202183-88 bloedstolling 202183-88 bloedverdunners 202183-88 cumarinederivaten 202183-88 dabigatran 202183-88 directe trombineremmers 202183-88 factor Xa-remmers 202183-88 fenprocoumon 202183-88 idarucizumab 202183-88 protrombinecomplexconcentraat 202183-88 rivaroxaban 202183-88 vitamine K-antagonisten 202183-88 doelgroep COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16
E
ECMO COVID-19 202178-82 IMV 202178-82 SARS-CoV-2 202178-82 beademing 202178-82 corticosteroïden 202178-82 covidpneumonie 202178-82 dexamethason 202178-82 hydrocortison 202178-82 inhalatiecorticosteroïden 202178-82 methylprednisolon 202178-82 pandemie 202178-82 zuurstoftherapie 202178-82 EGFR-tyrokinaseremmer Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 EMA FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 empagliflozine amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 epidemiologisch onderzoek bijwerkingen 20215-7 post-marketing surveillance 20215-7 registratieonderzoek 20215-7 vaccins 20215-7 vaccinvigilantie 20215-7 epidermale groeifactorreceptor EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 Erlotinib EGFR-tyrokinaseremmer 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 ertugliflozine amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 etesevimab SARS-CoV-2 202169-73 bamlanivimab 202169-73 casirivimab 202169-73 covid-19 202169-73 covidpandemie 202169-73 covidpatiënten 202169-73 imdevimab 202169-73 immuungecompromitteerden 202169-73 longcovid 202169-73 monoklonale antilichamen 202169-73 neutraliserende monoklonale antilichamen 202169-73 pandemie 202169-73 regdanvimab 202169-73 sotrovimab 202169-73 extramurale behandeling EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 ezetimib CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4
F
factor Xa-remmers DOAC 202183-88 PCC 202183-88 acenocoumarol 202183-88 andexanet alfa 202183-88 antidota 202183-88 apixaban 202183-88 bloedingen 202183-88 bloedstolling 202183-88 bloedverdunners 202183-88 cumarinederivaten 202183-88 dabigatran 202183-88 directe trombineremmers 202183-88 fenprocoumon 202183-88 idarucizumab 202183-88 protrombinecomplexconcentraat 202183-88 rivaroxaban 202183-88 vitamine K-antagonisten 202183-88 FDA EMA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 fenprocoumon DOAC 202183-88 PCC 202183-88 acenocoumarol 202183-88 andexanet alfa 202183-88 antidota 202183-88 apixaban 202183-88 bloedingen 202183-88 bloedstolling 202183-88 bloedverdunners 202183-88 cumarinederivaten 202183-88 dabigatran 202183-88 directe trombineremmers 202183-88 factor Xa-remmers 202183-88 idarucizumab 202183-88 protrombinecomplexconcentraat 202183-88 rivaroxaban 202183-88 vitamine K-antagonisten 202183-88 fenytoïne T3 202195-99 T4 202195-99 TRH 202195-99 TSH 202195-99 amiodaron 202195-99 asparaginase 202195-99 biotine 202195-99 carbamazepine 202195-99 danazol 202195-99 fluorouracil 202195-99 furosemide 202195-99 laboratoriumbepalingen 202195-99 levothyroxine 202195-99 liothyronine 202195-99 methadon 202195-99 niacine 202195-99 perfenazine 202195-99 schildklier 202195-99 schildklierfunctiestoornis 202195-99 schildklierhormonen 202195-99 schildklierwaarden 202195-99 thyroxine 202195-99 vitamine B3 202195-99 vitamine B8 202195-99 voedingssupplementen 202195-99 fluorouracil T3 202195-99 T4 202195-99 TRH 202195-99 TSH 202195-99 amiodaron 202195-99 asparaginase 202195-99 biotine 202195-99 carbamazepine 202195-99 danazol 202195-99 fenytoïne 202195-99 furosemide 202195-99 laboratoriumbepalingen 202195-99 levothyroxine 202195-99 liothyronine 202195-99 methadon 202195-99 niacine 202195-99 perfenazine 202195-99 schildklier 202195-99 schildklierfunctiestoornis 202195-99 schildklierhormonen 202195-99 schildklierwaarden 202195-99 thyroxine 202195-99 vitamine B3 202195-99 vitamine B8 202195-99 voedingssupplementen 202195-99 furosemide T3 202195-99 T4 202195-99 TRH 202195-99 TSH 202195-99 amiodaron 202195-99 asparaginase 202195-99 biotine 202195-99 carbamazepine 202195-99 danazol 202195-99 fenytoïne 202195-99 fluorouracil 202195-99 laboratoriumbepalingen 202195-99 levothyroxine 202195-99 liothyronine 202195-99 methadon 202195-99 niacine 202195-99 perfenazine 202195-99 schildklier 202195-99 schildklierfunctiestoornis 202195-99 schildklierhormonen 202195-99 schildklierwaarden 202195-99 thyroxine 202195-99 vitamine B3 202195-99 vitamine B8 202195-99 voedingssupplementen 202195-99
G
gangreen van Fournier amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 Gardasil AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 genotypering CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 gerandomiseerd onderzoek EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 gewichtsverlies GLP-1-agonist 202189-94 afvallen 202189-94 bloedglucoseverlagende geneesmiddelen 202189-94 diabetes mellitus type 2 202189-94 liraglutide 202189-94 obesitas 202189-94 overgewicht 202189-94 semaglutide 202189-94 GLP-1-agonist afvallen 202189-94 bloedglucoseverlagende geneesmiddelen 202189-94 diabetes mellitus type 2 202189-94 gewichtsverlies 202189-94 liraglutide 202189-94 obesitas 202189-94 overgewicht 202189-94 semaglutide 202189-94 glucosespiegel amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46
H
hartfalen amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 hartritmestoornis aritmie 202117-20 atrium flutter 202117-20 atriumfibrilleren 202117-20 medisch hulpmiddel 202117-20 medische app 202117-20 screening 202117-20 hba1c amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 hersenbloeding CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 herseninfarct CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 HPV AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 humaan papillomavirus AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 hydrocortison COVID-19 202178-82 ECMO 202178-82 IMV 202178-82 SARS-CoV-2 202178-82 beademing 202178-82 corticosteroïden 202178-82 covidpneumonie 202178-82 dexamethason 202178-82 inhalatiecorticosteroïden 202178-82 methylprednisolon 202178-82 pandemie 202178-82 zuurstoftherapie 202178-82
I
idarucizumab DOAC 202183-88 PCC 202183-88 acenocoumarol 202183-88 andexanet alfa 202183-88 antidota 202183-88 apixaban 202183-88 bloedingen 202183-88 bloedstolling 202183-88 bloedverdunners 202183-88 cumarinederivaten 202183-88 dabigatran 202183-88 directe trombineremmers 202183-88 factor Xa-remmers 202183-88 fenprocoumon 202183-88 protrombinecomplexconcentraat 202183-88 rivaroxaban 202183-88 vitamine K-antagonisten 202183-88 imdevimab SARS-CoV-2 202169-73 bamlanivimab 202169-73 casirivimab 202169-73 covid-19 202169-73 covidpandemie 202169-73 covidpatiënten 202169-73 etesevimab 202169-73 immuungecompromitteerden 202169-73 longcovid 202169-73 monoklonale antilichamen 202169-73 neutraliserende monoklonale antilichamen 202169-73 pandemie 202169-73 regdanvimab 202169-73 sotrovimab 202169-73 immuungecompromitteerden SARS-CoV-2 202169-73 bamlanivimab 202169-73 casirivimab 202169-73 covid-19 202169-73 covidpandemie 202169-73 covidpatiënten 202169-73 etesevimab 202169-73 imdevimab 202169-73 longcovid 202169-73 monoklonale antilichamen 202169-73 neutraliserende monoklonale antilichamen 202169-73 pandemie 202169-73 regdanvimab 202169-73 sotrovimab 202169-73 IMV COVID-19 202178-82 ECMO 202178-82 SARS-CoV-2 202178-82 beademing 202178-82 corticosteroïden 202178-82 covidpneumonie 202178-82 dexamethason 202178-82 hydrocortison 202178-82 inhalatiecorticosteroïden 202178-82 methylprednisolon 202178-82 pandemie 202178-82 zuurstoftherapie 202178-82 in-stent-restenose MACE 202174-77 canakinumab 202174-77 cardiovasculaire mortaliteit 202174-77 colchicine 202174-77 coronaire hartziekten 202174-77 myocardinfarct 202174-77 secundaire preventie 202174-77 stents 202174-77 inhalatiecorticosteroïden COVID-19 202178-82 ECMO 202178-82 IMV 202178-82 SARS-CoV-2 202178-82 beademing 202178-82 corticosteroïden 202178-82 covidpneumonie 202178-82 dexamethason 202178-82 hydrocortison 202178-82 methylprednisolon 202178-82 pandemie 202178-82 zuurstoftherapie 202178-82 interleukine-6-antagonist COVID-19 202163-68 SARS-CoV-2 202163-68 corticosteroïden 202163-68 covidpneumonie 202163-68 dexamethason 202163-68 pandemie 202163-68 sarilumab 202163-68 tocilizumab 202163-68 zuurstoftherapie 202163-68 intermediate metabolizer CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12
J
Janssen Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34
K
keto-acidose amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46
L
laboratoriumbepalingen T3 202195-99 T4 202195-99 TRH 202195-99 TSH 202195-99 amiodaron 202195-99 asparaginase 202195-99 biotine 202195-99 carbamazepine 202195-99 danazol 202195-99 fenytoïne 202195-99 fluorouracil 202195-99 furosemide 202195-99 levothyroxine 202195-99 liothyronine 202195-99 methadon 202195-99 niacine 202195-99 perfenazine 202195-99 schildklier 202195-99 schildklierfunctiestoornis 202195-99 schildklierhormonen 202195-99 schildklierwaarden 202195-99 thyroxine 202195-99 vitamine B3 202195-99 vitamine B8 202195-99 voedingssupplementen 202195-99 LDL-cholesterol CVA 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 leverenzymen CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 levothyroxine T3 202195-99 T4 202195-99 TRH 202195-99 TSH 202195-99 amiodaron 202195-99 asparaginase 202195-99 biotine 202195-99 carbamazepine 202195-99 danazol 202195-99 fenytoïne 202195-99 fluorouracil 202195-99 furosemide 202195-99 laboratoriumbepalingen 202195-99 liothyronine 202195-99 methadon 202195-99 niacine 202195-99 perfenazine 202195-99 schildklier 202195-99 schildklierfunctiestoornis 202195-99 schildklierhormonen 202195-99 schildklierwaarden 202195-99 thyroxine 202195-99 vitamine B3 202195-99 vitamine B8 202195-99 voedingssupplementen 202195-99 liothyronine T3 202195-99 T4 202195-99 TRH 202195-99 TSH 202195-99 amiodaron 202195-99 asparaginase 202195-99 biotine 202195-99 carbamazepine 202195-99 danazol 202195-99 fenytoïne 202195-99 fluorouracil 202195-99 furosemide 202195-99 laboratoriumbepalingen 202195-99 levothyroxine 202195-99 methadon 202195-99 niacine 202195-99 perfenazine 202195-99 schildklier 202195-99 schildklierfunctiestoornis 202195-99 schildklierhormonen 202195-99 schildklierwaarden 202195-99 thyroxine 202195-99 vitamine B3 202195-99 vitamine B8 202195-99 voedingssupplementen 202195-99 liraglutide GLP-1-agonist 202189-94 afvallen 202189-94 bloedglucoseverlagende geneesmiddelen 202189-94 diabetes mellitus type 2 202189-94 gewichtsverlies 202189-94 obesitas 202189-94 overgewicht 202189-94 semaglutide 202189-94 longcovid SARS-CoV-2 202169-73 bamlanivimab 202169-73 casirivimab 202169-73 covid-19 202169-73 covidpandemie 202169-73 covidpatiënten 202169-73 etesevimab 202169-73 imdevimab 202169-73 immuungecompromitteerden 202169-73 monoklonale antilichamen 202169-73 neutraliserende monoklonale antilichamen 202169-73 pandemie 202169-73 regdanvimab 202169-73 sotrovimab 202169-73
M
MACE canakinumab 202174-77 cardiovasculaire mortaliteit 202174-77 colchicine 202174-77 coronaire hartziekten 202174-77 in-stent-restenose 202174-77 myocardinfarct 202174-77 secundaire preventie 202174-77 stents 202174-77 medisch hulpmiddel aritmie 202117-20 atrium flutter 202117-20 atriumfibrilleren 202117-20 hartritmestoornis 202117-20 medische app 202117-20 screening 202117-20 medische app aritmie 202117-20 atrium flutter 202117-20 atriumfibrilleren 202117-20 hartritmestoornis 202117-20 medisch hulpmiddel 202117-20 screening 202117-20 messenger-RNA COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 meta-analyse Aktiprol® 202121-28 amisulpride 202121-28 antipsychotica 202121-28 bijwerkingen 202121-28 netwerk meta-analyse 202121-28 metformine amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 methadon T3 202195-99 T4 202195-99 TRH 202195-99 TSH 202195-99 amiodaron 202195-99 asparaginase 202195-99 biotine 202195-99 carbamazepine 202195-99 danazol 202195-99 fenytoïne 202195-99 fluorouracil 202195-99 furosemide 202195-99 laboratoriumbepalingen 202195-99 levothyroxine 202195-99 liothyronine 202195-99 niacine 202195-99 perfenazine 202195-99 schildklier 202195-99 schildklierfunctiestoornis 202195-99 schildklierhormonen 202195-99 schildklierwaarden 202195-99 thyroxine 202195-99 vitamine B3 202195-99 vitamine B8 202195-99 voedingssupplementen 202195-99 methylprednisolon COVID-19 202178-82 ECMO 202178-82 IMV 202178-82 SARS-CoV-2 202178-82 beademing 202178-82 corticosteroïden 202178-82 covidpneumonie 202178-82 dexamethason 202178-82 hydrocortison 202178-82 inhalatiecorticosteroïden 202178-82 pandemie 202178-82 zuurstoftherapie 202178-82 Moderna COVID-19 202113-16 Comirnaty 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 monoklonale antilichamen SARS-CoV-2 202169-73 bamlanivimab 202169-73 casirivimab 202169-73 covid-19 202169-73 covidpandemie 202169-73 covidpatiënten 202169-73 etesevimab 202169-73 imdevimab 202169-73 immuungecompromitteerden 202169-73 longcovid 202169-73 neutraliserende monoklonale antilichamen 202169-73 pandemie 202169-73 regdanvimab 202169-73 sotrovimab 202169-73 mRNA COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 myocardinfarct CVA 20211-4 EMA 202157-62 FDA 202157-62 LDL-cholesterol 20211-4 MACE 202174-77 TIA 20211-4 angina 20211-4 beroerte 20211-4 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 canakinumab 202174-77 cardiovasculair 20211-4 cardiovasculaire mortaliteit 202174-77 cerebrovasculair 20211-4 colchicine 202174-77 coronaire hartziekten 202174-77 diabetes 202157-62 ezetimib 20211-4 gerandomiseerd onderzoek 202157-62 hersenbloeding 20211-4 herseninfarct 20211-4 in-stent-restenose 202174-77 observationeel onderzoek 202157-62 registratie 202157-62 revascularisatie 20211-4 richtlijnen 20211-4 richtlijnen 202157-62 rosiglitazon 202157-62 secundaire preventie 202174-77 statinen 20211-4 stents 202174-77 streefwaarden 20211-4
N
netwerk meta-analyse Aktiprol® 202121-28 amisulpride 202121-28 antipsychotica 202121-28 bijwerkingen 202121-28 meta-analyse 202121-28 neutraliserende monoklonale antilichamen SARS-CoV-2 202169-73 bamlanivimab 202169-73 casirivimab 202169-73 covid-19 202169-73 covidpandemie 202169-73 covidpatiënten 202169-73 etesevimab 202169-73 imdevimab 202169-73 immuungecompromitteerden 202169-73 longcovid 202169-73 monoklonale antilichamen 202169-73 pandemie 202169-73 regdanvimab 202169-73 sotrovimab 202169-73 niacine T3 202195-99 T4 202195-99 TRH 202195-99 TSH 202195-99 amiodaron 202195-99 asparaginase 202195-99 biotine 202195-99 carbamazepine 202195-99 danazol 202195-99 fenytoïne 202195-99 fluorouracil 202195-99 furosemide 202195-99 laboratoriumbepalingen 202195-99 levothyroxine 202195-99 liothyronine 202195-99 methadon 202195-99 perfenazine 202195-99 schildklier 202195-99 schildklierfunctiestoornis 202195-99 schildklierhormonen 202195-99 schildklierwaarden 202195-99 thyroxine 202195-99 vitamine B3 202195-99 vitamine B8 202195-99 voedingssupplementen 202195-99 niet-kleincellig longcarcinoom EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 overleving 202135-40 progressievrij 202135-40 nonavalent AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 NSCLC EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40
O
obesitas GLP-1-agonist 202189-94 afvallen 202189-94 bloedglucoseverlagende geneesmiddelen 202189-94 diabetes mellitus type 2 202189-94 gewichtsverlies 202189-94 liraglutide 202189-94 overgewicht 202189-94 semaglutide 202189-94 observationeel onderzoek EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon